BETHEL, Conn., July 20, 2007 (PRIME NEWSWIRE) -- Aduromed Industries Inc. (OTCBB:ADRM), a leading manufacturer of medical waste treatment systems, today announced an additional sale of its MC4 Series system to its partner ARAMARK. This MedClean(r) system will be installed at a hospital site in Southern California and is expected to treat over 450,000 pounds of medical waste annually. The system is also equipped with a component that enables the hospital to destroy its confidential documents in full compliance with HIPAA regulations, avoiding costly outsourcing and further enhancing the return on their investment. This will be Aduromed's twelfth MedClean System sale to ARAMARK. The system is projected to be installed and commence operation before year-end.
"Our relationship with ARAMARK, based on the valuable benefits our MedClean system brings to their clients, is generating an increasing revenue stream for Aduromed," said Damien R. Tanaka, CEO and President of Aduromed. "We believe that this relationship with ARAMARK, together with our own independent sales and marketing activities, will continue to contribute to increased sales and help spur revenue growth well into the future."
This contract was awarded to replace an existing competitive technology that had been in use at this institution for several years. The new installation of the MC4 Series system indicates progress for the waste stream management program designed by ARAMARK, known as the WasteStream QL program initiative, which features Aduromed's MedClean System.
About Aduromed Corporation
Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is one of the largest modern day providers of systems for the onsite disposal of medical waste that incorporates the design, installation and servicing of turnkey systems to treat infectious regulated medical waste (RMW). ADRM provides proprietary equipment and systems for efficient, safe, cost effective and legally compliant alternative solutions to incineration or off-site hauling of RMW, as well as to other treatment technologies and methodologies. With a strong base of suppliers and clients ADRM is positioned for significant growth within the medical waste industry.
Aduromed's MedClean Series System treats and processes all forms of RMW, sterilizing the waste prior to rendering it unrecognizable. Through use of a unique and proprietary dual-stage shredding machine, this System converts such waste into safe solid waste (SSW) for disposal into a normal landfill. The System is part of Aduromed's MedClean Program, which incorporates collection, transportation and processing of medical waste on site, and eliminates any manual handling or transfer of the medical waste until its conversion into SSW, thereby protecting the operator and limiting liability for the institutions using the Program. The Program provides the further benefit of eliminating the transportation of RMW over public roadways. The unique design and arrangement of the System's components make it the smallest footprint within an industry where real estate is at a premium. Each MedClean Series System installation is sized appropriately to ensure ample capacity to treat and process medical waste efficiently and effectively.
The current U.S. medical waste market is estimated to be $3 billion. Further information on Aduromed can be found at www.aduromed.com and in filings with the Securities and Exchange Commission found at www.sec.gov.
This press release and the information incorporated by reference may include "forward-looking statements": within the meaning of applicable Federal Securities Laws. The Company intends the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. All statements regarding the Company's expected financial position and operating results, its business strategy, its financing plans and the outcome of any contingencies are forward looking statements. The forward-looking statements are based on current estimates and projections about our industry and our business. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements, including those set forth in our most recent Annual Report on Form 10-KSB for the year ended December 31, 2006, filed with the SEC on March 30, 2007, and other filings with the SEC, and are subject to change at any time. The Company assumes no obligation to update publicly the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as may be required by law.